The Technical Analyst
Applied Genetic [AGTC]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Applied Genetic Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.394
/ 30 nov 2022 @ 16:00
| RATING 2022-12-09 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.270 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.270 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.366 - 0.422 ( +/- 7.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-11-30 | Robinson James A. Jr. | Sell | 25 000 | Stock Option (Right to Buy) |
| 2022-11-30 | Vanlent Anne | Sell | 14 000 | Stock Option (Right to Buy) |
| 2022-11-30 | Rosen James | Sell | 1 000 | Common Stock |
| 2022-11-30 | Rosen James | Sell | 14 000 | Stock Option (Right to Buy) |
| 2022-11-30 | Aliski William | Sell | 8 500 | Common Stock |
| INSIDER POWER |
|---|
| -16.96 |
| Last 91 transactions |
| Buy: 4 369 607 | Sell: 1 870 885 |
Forecast:
01:40 - $0.333
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.394 (0.00% ) |
| Volume | 0.765 mill |
| Avg. Vol. | 1.316 mill |
| % of Avg. Vol | 58.10 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AGTC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AGTC
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Latest Press Releases
2022-09-01 08:00:00 - Press Release
Agtc To Participate In Upcoming Investor Conferences
Gainesville, fla., and cambridge, mass., sept. 01, 2022 (globe newswire) -- applied genetic technologies corporation (“agtc” or the “company”) (nasdaq: agtc), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (aav)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
2022-08-01 16:05:00 - Press Release
Agtc To Participate In Upcoming Investor Conferences
Gainesville, fla. and cambridge, mass., aug. 01, 2022 (globe newswire) -- applied genetic technologies corporation (“agtc” or the “company”) (nasdaq: agtc), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (aav)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
2022-07-07 08:00:00 - Press Release
Agtc To Present At Upcoming American Society Of Retina Specialists Annual Meeting
July 7, 2022 at 8:00 am edt july 7, 2022 at 8:00 am edt
2022-06-09 08:00:00 - Press Release
Aurion Biotech Appoints Dr. Michael Goldstein As President And Chief Medical Officer
Seattle, boston & tokyo--(business wire)--aurion biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed michael goldstein, m.d., m.b.a., as president and chief medical officer. dr. goldstein will lead the company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothe
2022-03-08 16:05:00 - Press Release
Agtc To Participate In Upcoming Investor Conferences
Gainesville, fla. and cambridge, mass., march 08, 2022 (globe newswire) -- applied genetic technologies corporation (nasdaq: agtc), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (aav)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (irds), today announced that management will be participating in the following virtual investor conferences:
Latest News
2022-10-25 08:29:21 - PennyStocks
Make Money With Penny Stocks in November? 3 Methods to Use
Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-01 08:00:00 - GlobeNewsWire
AGTC to Participate in Upcoming Investor Conferences
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
2022-08-01 16:05:00 - GlobeNewsWire
AGTC to Participate in Upcoming Investor Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
2022-07-07 08:00:00 - GlobeNewsWire
AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
2022-03-08 16:05:00 - GlobeNewsWire
AGTC to Participate in Upcoming Investor Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that management will be participating in the following virtual investor conferences:
2022-02-14 13:01:03 - Seeking Alpha
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript
2022-02-07 08:00:00 - GlobeNewsWire
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter ended December 31, 2021 before the market opens on Monday, February 14, 2022. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.
2021-11-09 09:56:31 - Zacks Investment Research
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-10-19 08:00:00 - GlobeNewsWire
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.
2021-10-14 17:00:00 - GlobeNewsWire
AGTC Announces Two Key Leadership Team Appointments
- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -